<DOC>
	<DOCNO>NCT01168141</DOCNO>
	<brief_summary>This prospective study patient castrate-resistant prostate cancer bone metastases undergo imaging , donate blood , bone marrow urine sample , possible primary tumour bone metastatic tissue , treatment ZD4054 , orally active specific endothelin-A antagonist . The sample use primarily biomarker study , hypothesize inform mechanism action drug . Magnetic Resonance Imaging ( MRI ) perform evaluate emerge functional imaging endpoint marker early response bone metastatic prostate cancer .</brief_summary>
	<brief_title>Window Study ZD4054 Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>histological confirmation prostate adenocarcinoma document evidence bone metastasis bone scan MRI biochemical progression prostate cancer surgically medically castrate serum testosterone â‰¤2.4nmol/L ECOG performance status 0 2 life expectancy 6 month . radiotherapy bone lesion prostatic bed within 4 week start study treatment . prior targeted cancer therapy ( gefitinib , bevacizumab ) systemic radionuclide therapy within 12 week start study treatment . current therapy , within 4 week study entry potent inhibitor CYP3A4 ( ketoconazole , itraconazole , ritonavir , indinavir , erythromycin , troleandomycin , clarithromycin , diltiazem verapamil ) , inhibitor CYPs 2D6 2C9 ( quinidine fluconazole ) , potent P450 inducer ( phenytoin , rifampicin , carbamazepine phenobarbitone ) definite suspect personal history family history adverse drug reaction , hypersensitivity drug endothelin antagonist ineligibility MRI scan include standard MRI criterion ( example , metal implant cochlear implant , cardiac pacemaker , heart valve , aneurysm clip metal fragment eye ) patient know allergic gadoliniumbased MRI contrast agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Castrate-resistant prostate cancer bone metastasis</keyword>
</DOC>